---
input_text: '[What is your diagnosis? Inveterate anterior shoulder dislocation].THERAPEUTIC
  APPROACHES IN SICKLE CELL DISEASE. Sickle cell disease, the most common genetic
  disease in France, is still burdened with morbidity and early mortality before the
  age of 50. When the first-line treatment, hydroxyurea, is insufficient or in the
  case of organic damage(s) (in particular cerebral vasculopathy), a therapeutic intensification
  must be considered. New molecules are now available, such as voxelotor and crizanlizumab,
  but only hematopoietic stem cell (HSC) transplantation can cure the disease. Allogeneic
  HSC transplantation during childhood with a sibling donor is the reference but it
  is now possible to perform this procedure in adults with a reduced pre-transplant
  conditioning. Gene therapy, which consists of an autograft of genetically modified
  HSCs, has obtained promising results but has not yet demonstrated a complete cure
  of the disease (protocols underway). The toxicity of myeloablative conditioning
  (used in pediatrics or for gene therapy), particularly the sterility induced, and
  the risk of graft-versushost disease (for allogeneic transplantation) are limiting
  factors of these treatments.'
raw_completion_output: |-
  primary_disease: Sickle cell disease
  medical_actions: Hydroxyurea treatment; Therapeutic intensification; Voxelotor use; Crizanlizumab use; Hematopoietic stem cell (HSC) transplantation; Reduced pre-transplant conditioning; Gene therapy; Myeloablative conditioning
  symptoms: Morbidity; Early mortality; Cerebral vasculopathy
  chemicals: Hydroxyurea; Voxelotor; Crizanlizumab
  action_annotation_relationships: Hydroxyurea treatment TREATS morbidity IN Sickle cell disease; Hydroxyurea treatment PREVENTS early mortality IN Sickle cell disease; Therapeutic intensification TREATS cerebral vasculopathy IN Sickle cell disease; Voxelotor use TREATS morbidity IN Sickle cell disease; Crizanlizumab use TREATS morbidity IN Sickle cell disease; Hematopoietic stem cell (HSC) transplantation CURES Sickle cell disease; Reduced pre-transplant conditioning TREATS morbidity IN Sickle cell disease; Gene therapy TREATS morbidity IN Sickle cell disease; Myeloablative conditioning PREVENTS early mortality IN Sickle cell disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Myeloablative conditioning PREVENTS early mortality IN Sickle cell disease

  ===

extracted_object:
  primary_disease: MONDO:0011382
  medical_actions:
    - Hydroxyurea treatment
    - Therapeutic intensification
    - Voxelotor use
    - Crizanlizumab use
    - MAXO:0000747
    - Reduced pre-transplant conditioning
    - MAXO:0001001
    - Myeloablative conditioning
  symptoms:
    - Morbidity
    - Early mortality
    - Cerebral vasculopathy
  chemicals:
    - CHEBI:44423
    - Voxelotor
    - Crizanlizumab
  action_annotation_relationships:
    - subject: treatment
      predicate: TREATS
      object: morbidity
      qualifier: MONDO:0011382
      subject_extension: CHEBI:44423
    - subject: treatment
      predicate: PREVENTS
      object: early mortality
      qualifier: MONDO:0011382
      subject_extension: CHEBI:44423
    - subject: Therapeutic intensification
      predicate: TREATS
      object: cerebral vasculopathy
      qualifier: MONDO:0011382
    - subject: use
      predicate: TREATS
      object: morbidity
      qualifier: MONDO:0011382
      subject_extension: voxelotor
    - subject: Crizanlizumab use
      predicate: TREATS
      object: morbidity
      qualifier: MONDO:0011382
      subject_extension: Crizanlizumab
    - subject: <transplantation>
      predicate: <CURES>
      object: <Sickle cell disease>
      subject_extension: <Hematopoietic stem cell>
    - subject: <Reduced pre-transplant conditioning>
      predicate: <TREATS>
      object: <morbidity>
      qualifier: <Sickle cell disease>
      subject_extension: <Reduced pre-transplant conditioning>
    - subject: MAXO:0001001
      predicate: TREATS
      object: morbidity
      qualifier: MONDO:0011382
    - subject: Myeloablative conditioning
      predicate: PREVENTS
      object: early mortality
      qualifier: MONDO:0011382
named_entities:
  - id: MONDO:0007374
    label: Sickle Cell Disease (SCD)
  - id: CHEBI:44423
    label: Hydroxyurea
  - id: CHEBI:18050
    label: L-glutamine
  - id: MAXO:0001298
    label: therapy
  - id: MONDO:0011382
    label: Sickle Cell Disease
  - id: MONDO:0005290
    label: Rhabdomyolysis
  - id: MAXO:0001121
    label: kidney biopsy
  - id: MAXO:0000387
    label: muscle biopsy
  - id: HP:0001919
    label: acute kidney injury (AKI)
  - id: CHEBI:7044
    label: Myoglobin
  - id: MAXO:0000950
    label: supportive care
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: MAXO:0000747
    label: hematopoietic stem cell transplantation (HSCT)
  - id: MAXO:0009101
    label: early intervention
  - id: MONDO:0100096
    label: COVID-19
  - id: MAXO:0000756
    label: blood transfusion
  - id: MAXO:0001001
    label: gene therapy
  - id: HP:0004936
    label: venous thrombosis
  - id: MONDO:0005266
    label: diabetic retinopathy
  - id: MONDO:0002303
    label: central retinal vein occlusion
  - id: HP:0100543
    label: Cognitive dysfunction
  - id: MONDO:0013517
    label: beta-thalassemia
  - id: HP:0012531
    label: Pain
  - id: MAXO:0000457
    label: Pain management
  - id: HP:0000739
    label: anxiety
  - id: HP:0000716
    label: depression
  - id: CHEBI:6716
    label: depot medroxyprogesterone (DMPA)
  - id: CHEBI:59826
    label: progestin
  - id: MONDO:0002049
    label: Thrombocytopenia
  - id: MAXO:0001017
    label: Vaccination
  - id: MONDO:0005632
    label: Acute chest syndrome
  - id: CHEBI:41879
    label: dexamethasone
  - id: CHEBI:17303
    label: morphine
  - id: CHEBI:16480
    label: nitric oxide
  - id: CHEBI:28304
    label: heparin
  - id: MONDO:0013730
    label: graft versus host disease (GvHD)
  - id: MAXO:0010030
    label: Bone marrow transplantation
  - id: MAXO:0000004
    label: Surgical intervention
  - id: HP:0200023
    label: Priapism
  - id: HP:0001945
    label: pyrexia
  - id: HP:0002019
    label: constipation
  - id: HP:0001903
    label: decreased haemoglobin
  - id: CHEBI:26710
    label: NaCl
  - id: MAXO:0000530
    label: Carrier screening
  - id: HP:0002615
    label: Hypotension
  - id: HP:0001662
    label: Bradycardia
  - id: HP:0002098
    label: Respiratory distress
  - id: CHEBI:119915
    label: Fentanyl
  - id: HP:0000407
    label: Sensorineural hearing loss (SNHL)
  - id: HP:0001249
    label: Poor school performance
  - id: HP:0030645
    label: Risk of (central) auditory processing disorder
  - id: CHEBI:28901
    label: Busulfan
  - id: MAXO:0000750
    label: conditioning regimen
  - id: MONDO:0002280
    label: Anemia
  - id: MONDO:0005003
    label: Chronic Pancreatitis
  - id: MAXO:0000088
    label: Dietary interventions
  - id: MAXO:0035049
    label: Endoscopic retrograde cholangiopancreatography
  - id: CHEBI:35480
    label: Analgesic
  - id: CHEBI:22586
    label: Antioxidants
  - id: CHEBI:17334
    label: Penicillin
  - id: HP:0001297
    label: stroke
  - id: HP:0003826
    label: Stillbirths
  - id: HP:0100806
    label: Sepsis
  - id: HP:0011891
    label: Postpartum hemorrhage
  - id: MONDO:0002050
    label: Depression
  - id: HP:0012418
    label: Hypoxia
  - id: CHEBI:17230
    label: Homocysteine
  - id: CHEBI:16811
    label: Methionine
  - id: MONDO:0005136
    label: Malaria
  - id: HP:0001518
    label: Low birth weight
  - id: CHEBI:38068
    label: Antimalarial
  - id: MONDO:0001754
    label: Eclampsia
  - id: HP:0011902
    label: Abnormal hemoglobin
  - id: CHEBI:223316
    label: Artemisinin
  - id: CHEBI:195280
    label: Artemether
  - id: CHEBI:156095
    label: Lumefantrine
  - id: CHEBI:63918
    label: Artesunate
  - id: CHEBI:2674
    label: Amodiaquine
  - id: MAXO:0009065
    label: Intravenous push (IVP) analgesia
  - id: MONDO:0010088
    label: Musculoskeletal diseases (MSD)
  - id: MONDO:0002081
    label: Musculoskeletal diseases
  - id: MONDO:0002146
    label: Hypogonadism
  - id: MONDO:0009061
    label: cystic fibrosis
  - id: MAXO:0000079
    label: genetic counseling
  - id: MONDO:0020380
    label: Sickle Cell Anaemia (SCA)
  - id: HP:0001511
    label: intrauterine growth restriction
  - id: HP:0100602
    label: pre-eclampsia
  - id: HP:0005268
    label: miscarriage
  - id: HP:0001622
    label: preterm delivery
  - id: HP:0011419
    label: placental abruption
  - id: CHEBI:15365
    label: aspirin
  - id: CHEBI:15552
    label: prostacyclin
  - id: CHEBI:26995
    label: thromboxane
  - id: MAXO:0001077
    label: Splenectomy
  - id: HP:0010972
    label: Ineffective erythropoiesis
  - id: HP:0004387
    label: enterocolitis
  - id: MONDO:0007100
    label: transthyretin amyloidosis
  - id: HP:0001139
    label: conditional transcranial Doppler (TCD) flow velocities
